JP2023552816A5 - - Google Patents
Info
- Publication number
- JP2023552816A5 JP2023552816A5 JP2023534899A JP2023534899A JP2023552816A5 JP 2023552816 A5 JP2023552816 A5 JP 2023552816A5 JP 2023534899 A JP2023534899 A JP 2023534899A JP 2023534899 A JP2023534899 A JP 2023534899A JP 2023552816 A5 JP2023552816 A5 JP 2023552816A5
- Authority
- JP
- Japan
- Prior art keywords
- invention described
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063124064P | 2020-12-11 | 2020-12-11 | |
| US63/124,064 | 2020-12-11 | ||
| US202063130106P | 2020-12-23 | 2020-12-23 | |
| US63/130,106 | 2020-12-23 | ||
| PCT/US2021/062946 WO2022125982A1 (en) | 2020-12-11 | 2021-12-10 | Compositions and methods for reducing mhc class ii in a cell |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023552816A JP2023552816A (ja) | 2023-12-19 |
| JP2023552816A5 true JP2023552816A5 (enExample) | 2024-12-19 |
Family
ID=80168106
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023534899A Pending JP2023552816A (ja) | 2020-12-11 | 2021-12-10 | 細胞内のｍｈｃクラスｉｉを低減する組成物及び方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20240016934A1 (enExample) |
| EP (1) | EP4259783A1 (enExample) |
| JP (1) | JP2023552816A (enExample) |
| KR (1) | KR20230130635A (enExample) |
| AU (1) | AU2021396403A1 (enExample) |
| CA (1) | CA3204997A1 (enExample) |
| CL (2) | CL2023001688A1 (enExample) |
| CO (1) | CO2023008922A2 (enExample) |
| CR (1) | CR20230303A (enExample) |
| IL (1) | IL303505A (enExample) |
| MX (1) | MX2023006878A (enExample) |
| TW (1) | TW202235617A (enExample) |
| WO (1) | WO2022125982A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4544058A1 (en) * | 2022-06-23 | 2025-04-30 | Chroma Medicine, Inc. | Compositions and methods for epigenetic regulation of ciita expression |
| US20240189355A1 (en) * | 2022-11-14 | 2024-06-13 | WUGEN, Inc. | Hypoimmunogenic cells having targeted modifications in mhc class-i genes and methods of use |
| CN118922551A (zh) * | 2023-01-30 | 2024-11-08 | 南京北恒生物科技有限公司 | 用于CRISPR-Cas基因编辑系统的方法及组合物 |
| KR102740042B1 (ko) | 2023-07-12 | 2024-12-06 | ㈜바이오솔빅스 | 인간 전분화능 줄기세포로 유래된 심장 오가노이드 제조방법, 효능 및 독성 평가 기술 |
| WO2025038646A1 (en) | 2023-08-14 | 2025-02-20 | Intellia Therapeutics, Inc. | Cd70 car-t compositions and methods for cell-based therapy |
| WO2025038637A1 (en) | 2023-08-14 | 2025-02-20 | Intellia Therapeutics, Inc. | Compositions and methods for genetically modifying transforming growth factor beta receptor type 2 (tgfβr2) |
| TW202515994A (zh) | 2023-08-14 | 2025-04-16 | 美商英特利亞醫療公司 | 用於對ｃｄ７０進行基因修飾之組合物及方法 |
| WO2025038648A1 (en) | 2023-08-14 | 2025-02-20 | Intellia Therapeutics, Inc. | Compositions and methods for genetically modifying transforming growth factor beta receptor type 2 (tgfβr2) |
| WO2025049432A1 (en) * | 2023-08-28 | 2025-03-06 | Intellia Therapeutics, Inc. | Methods for editing hla-a in cells pre-screened for the absence of one or both alleles of hla-h*01 |
| WO2025049481A1 (en) * | 2023-08-28 | 2025-03-06 | Intellia Therapeutics, Inc. | Methods of editing an hla-a gene in vitro |
| WO2025128871A2 (en) | 2023-12-13 | 2025-06-19 | Renagade Therapeutics Management Inc. | Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents |
| WO2025255308A1 (en) | 2024-06-07 | 2025-12-11 | Intellia Therapeutics, Inc. | Cd8 co-receptor chimeric polypeptides in tcr cell therapy |
| WO2026143185A1 (en) | 2024-12-23 | 2026-07-02 | Ensoma Aps | Engineered rna-guided dna-binding polypeptides |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5585481A (en) | 1987-09-21 | 1996-12-17 | Gen-Probe Incorporated | Linking reagents for nucleotide probes |
| US5378825A (en) | 1990-07-27 | 1995-01-03 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogs |
| ATE515510T1 (de) | 1991-12-24 | 2011-07-15 | Isis Pharmaceuticals Inc | Durch dna-abschnitte unterbrochene modifizierte oligonukleotide |
| EP0760008A1 (en) | 1994-05-19 | 1997-03-05 | Dako A/S | Pna probes for detection of neisseria gonorrhoeae and chlamydia trachomatis |
| CN103668470B (zh) | 2012-09-12 | 2015-07-29 | 上海斯丹赛生物技术有限公司 | 一种dna文库及构建转录激活子样效应因子核酸酶质粒的方法 |
| PT2931898E (pt) | 2012-12-12 | 2016-06-16 | Harvard College | Manipulação e otimização de sistemas, métodos e composições para manipulação de sequências com domínios funcionais |
| WO2014093694A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes |
| IL308158A (en) | 2012-12-17 | 2023-12-01 | Harvard College | Rna-guided human genome engineering |
| US20150166984A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting alpha-antitrypsin point mutations |
| CN106794141B (zh) | 2014-07-16 | 2021-05-28 | 诺华股份有限公司 | 将核酸包封在脂质纳米粒主体中的方法 |
| ES2688035T3 (es) | 2014-08-29 | 2018-10-30 | Gemoab Monoclonals Gmbh | Receptor de antígeno universal que expresa células inmunes para direccionamiento de antígenos múltiples diversos, procedimiento para fabricación del mismo y utilización del mismo para tratamiento de cáncer, infecciones y enfermedades autoinmunes |
| AU2016226077B2 (en) | 2015-03-03 | 2021-12-23 | The General Hospital Corporation | Engineered CRISPR-Cas9 nucleases with altered PAM specificity |
| EP3294342A4 (en) * | 2015-05-08 | 2018-11-07 | President and Fellows of Harvard College | Universal donor stem cells and related methods |
| WO2017093969A1 (en) * | 2015-12-04 | 2017-06-08 | Novartis Ag | Compositions and methods for immunooncology |
| ES3030658T3 (en) | 2016-03-30 | 2025-07-01 | Intellia Therapeutics Inc | Lipid nanoparticle formulations for crispr/cas components |
| WO2018073393A2 (en) | 2016-10-19 | 2018-04-26 | Cellectis | Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy |
| EP3551757A1 (en) | 2016-12-08 | 2019-10-16 | Intellia Therapeutics, Inc. | Modified guide rnas |
| JP7170666B2 (ja) | 2017-05-08 | 2022-11-14 | プレシジョン バイオサイエンシズ，インク． | 操作された抗原受容体をコードする核酸分子及び阻害性核酸分子、並びにそれらの使用方法 |
| BR112019023608A2 (pt) * | 2017-05-12 | 2020-05-26 | Crispr Therapeutics Ag | Materiais e métodos para células manipuladas e seus usos em imuno-oncologia |
| EP3688162B1 (en) | 2017-09-29 | 2024-03-06 | Intellia Therapeutics, Inc. | Formulations |
| AU2018383712B2 (en) * | 2017-12-11 | 2025-09-04 | Editas Medicine, Inc. | Cpf1-related methods and compositions for gene editing |
| WO2019147805A2 (en) | 2018-01-26 | 2019-08-01 | The Board Of Trustees Of The Leland Stanford Junior University | Regulatory t cells targeted with chimeric antigen receptors |
| US11447769B2 (en) | 2018-03-27 | 2022-09-20 | The Trustees Of The University Of Pennsylvania | Modified immune cells having enhanced function and methods for screening for same |
| JP7832761B2 (ja) | 2018-06-08 | 2026-03-18 | インテリア セラピューティクス，インコーポレイテッド | 遺伝子編集のための修飾されたガイドｒｎａ |
| WO2019237035A1 (en) * | 2018-06-08 | 2019-12-12 | Intellia Therapeutics, Inc. | Compositions and methods for immunooncology |
| EP3581200A1 (en) | 2018-06-13 | 2019-12-18 | GEMoaB Monoclonals GmbH | Reversed universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders |
| CN113166743B (zh) | 2018-10-15 | 2026-04-07 | 马萨诸塞大学 | Nme2cas9-脱氨酶融合蛋白的可编程dna碱基编辑 |
| CA3116132A1 (en) | 2018-10-16 | 2020-04-23 | Intellia Therapeutics, Inc. | Compositions and methods for immunotherapy |
| WO2020092057A1 (en) | 2018-10-30 | 2020-05-07 | Yale University | Compositions and methods for rapid and modular generation of chimeric antigen receptor t cells |
| SG11202108891QA (en) * | 2019-02-15 | 2021-09-29 | Harvard College | Universal donor stem cells and related methods |
-
2021
- 2021-12-10 MX MX2023006878A patent/MX2023006878A/es unknown
- 2021-12-10 CA CA3204997A patent/CA3204997A1/en active Pending
- 2021-12-10 KR KR1020237022783A patent/KR20230130635A/ko not_active Withdrawn
- 2021-12-10 AU AU2021396403A patent/AU2021396403A1/en not_active Abandoned
- 2021-12-10 JP JP2023534899A patent/JP2023552816A/ja active Pending
- 2021-12-10 EP EP21852082.3A patent/EP4259783A1/en active Pending
- 2021-12-10 WO PCT/US2021/062946 patent/WO2022125982A1/en not_active Ceased
- 2021-12-10 TW TW110146323A patent/TW202235617A/zh unknown
- 2021-12-10 CR CR20230303A patent/CR20230303A/es unknown
- 2021-12-10 IL IL303505A patent/IL303505A/en unknown
-
2023
- 2023-06-09 CL CL2023001688A patent/CL2023001688A1/es unknown
- 2023-06-09 US US18/332,390 patent/US20240016934A1/en active Pending
- 2023-07-05 CO CONC2023/0008922A patent/CO2023008922A2/es unknown
- 2023-10-17 CL CL2023003085A patent/CL2023003085A1/es unknown